RT Journal Article SR Electronic T1 How to use nesiritide in treating decompensated heart failure JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP 252 OP 256 VO 69 IS 3 A1 Mills, Roger M. A1 Hobbs, Robert E. YR 2002 UL http://www.ccjm.org/content/69/3/252.abstract AB Nesiritide (Natrecor), a synthetic formulation of B-type natriuretic peptide (BNP), is the first new parenteral agent to be approved for treating heart failure in more than a decade. In patients hospitalized with decompensated congestive heart failure, nesiritide promptly reduces pulmonary capillary wedge pressure, pulmonary arterial pressure, right atrial pressure, and systemic vascular resistance, resulting in clinical improvement.